Literature DB >> 7853367

Deletions in the 5' region of dystrophin and resulting phenotypes.

F Muntoni1, P Gobbi, C Sewry, T Sherratt, J Taylor, S K Sandhu, S Abbs, R Roberts, S V Hodgson, M Bobrow.   

Abstract

Deletions in the dystrophin gene give rise to both Duchenne and Becker muscular dystrophies. Good correlation is generally found between the severity of the phenotype and the effect of the deletion on the reading frame: deletions that disrupt the reading frame result in a severe phenotype, while in frame deletions are associated with a milder disease course. Rare exceptions to this rule, mainly owing to frameshift mutations in the 5' region of the gene (in particular deletions involving exons 3 to 7) which are associated with a milder than expected phenotype, have been reported previously. In order to characterise better the relationship between genotype and phenotype as a result of mutations arising in the 5' region of the gene, we have studied a large cohort of patients with small in frame and out of frame deletions in the first 13 exons of the dystrophin gene. Fifty-five patients with a deletion in this area were identified; approximately one third of them had a phenotype different from that theoretically expected. Patients were divided into two groups: (1) patients with a severe clinical phenotype despite the presence of a small, in frame deletion and (2) patients with a mild phenotype and an out of frame deletion. Noticeable examples observed in the first group were Duchenne boys with a deletion of exon 5, of exon 3, and of exons 3-13. In the second group we observed several patients with an intermediate or Becker phenotype and out of frame deletions involving not only the usual exons 3-7 but also 5-7 and 3-6. These data indicate that a high proportion of patients with a deletion in the 5' end of the gene have a phenotype that is not predictable on the basis of the effect of the deletion on the reading frame. The N-terminus of dystrophin has at least one actin binding domain that might be affected by the small, in frame deletions in this area. The effect of the in frame deletions of exon 3, 5, and 3-13 on this domain might account for the severe phenotype observed in these patients. Other mechanisms, such as unexpected effect of the deletion on splicing behaviour, might, however, also be implicated in determining the phenotype outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7853367      PMCID: PMC1016656          DOI: 10.1136/jmg.31.11.843

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  26 in total

1.  Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies.

Authors:  J Chelly; H Gilgenkrantz; M Lambert; G Hamard; P Chafey; D Récan; P Katz; A de la Chapelle; M Koenig; I B Ginjaar
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

2.  The interaction of actin with dystrophin.

Authors:  B A Levine; A J Moir; V B Patchell; S V Perry
Journal:  FEBS Lett       Date:  1990-04-09       Impact factor: 4.124

3.  Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction.

Authors:  A H Beggs; M Koenig; F M Boyce; L M Kunkel
Journal:  Hum Genet       Date:  1990-11       Impact factor: 4.132

4.  Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy.

Authors:  S B Malhotra; K A Hart; H J Klamut; N S Thomas; S E Bodrug; A H Burghes; M Bobrow; P S Harper; M W Thompson; P N Ray
Journal:  Science       Date:  1988-11-04       Impact factor: 47.728

5.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

6.  Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy.

Authors:  O M Scott; S A Hyde; C Goddard; V Dubowitz
Journal:  Muscle Nerve       Date:  1982-04       Impact factor: 3.217

7.  Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody.

Authors:  L V Nicholson; K Davison; G Falkous; C Harwood; E O'Donnell; C R Slater; J B Harris
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

Review 8.  Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations.

Authors:  R G Roberts; R J Gardner; M Bobrow
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

9.  Immunocytochemical localisation of complement components C8 and C9 in human diseased muscle. The role of complement in muscle fibre damage.

Authors:  C A Sewry; V Dubowitz; A Abraha; J P Luzio; A K Campbell
Journal:  J Neurol Sci       Date:  1987-11       Impact factor: 3.181

10.  Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin.

Authors:  D E Bulman; E G Murphy; E E Zubrzycka-Gaarn; R G Worton; P N Ray
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

View more
  20 in total

1.  Alternative splicing of dystrophin exon 4 in normal human muscle.

Authors:  S Torelli; F Muntoni
Journal:  Hum Genet       Date:  1996-04       Impact factor: 4.132

Review 2.  Mechanisms of resistance to pathogenesis in muscular dystrophies.

Authors:  J P Infante; V A Huszagh
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

3.  Magnetic Resonance Monitoring of Disease Progression in mdx Mice on Different Genetic Backgrounds.

Authors:  Ravneet Vohra; Abhinandan Batra; Sean C Forbes; Krista Vandenborne; Glenn A Walter
Journal:  Am J Pathol       Date:  2017-09       Impact factor: 4.307

4.  A novel cryptic exon identified in the 3' region of intron 2 of the human dystrophin gene.

Authors:  Van Khanh Tran; Zhujun Zhang; Mariko Yagi; Atsushi Nishiyama; Yasuaki Habara; Yasuhiro Takeshima; Masafumi Matsuo
Journal:  J Hum Genet       Date:  2005-08-30       Impact factor: 3.172

5.  Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy.

Authors:  Sebahattin Cirak; Lucy Feng; Karen Anthony; Virginia Arechavala-Gomeza; Silvia Torelli; Caroline Sewry; Jennifer E Morgan; Francesco Muntoni
Journal:  Mol Ther       Date:  2011-11-15       Impact factor: 11.454

6.  DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.

Authors:  Luca Bello; Lauren P Morgenroth; Heather Gordish-Dressman; Eric P Hoffman; Craig M McDonald; Sebahattin Cirak
Journal:  Neurology       Date:  2016-06-24       Impact factor: 9.910

7.  DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Michael T Howard; Jerry Mendell; Anne Connolly; Carol Saunders; Ann Modrcin; Majed Dasouki; Giacomo P Comi; Roberto Del Bo; Angela Pickart; Richard Jacobson; Richard Finkel; Livija Medne; Robert B Weiss
Journal:  Neuromuscul Disord       Date:  2009-09-29       Impact factor: 4.296

Review 8.  Large in-frame 5' deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature.

Authors:  Elizabeth M Gibbs; Florian Barthélémy; Emilie D Douine; Natalie C Hardiman; Perry B Shieh; Negar Khanlou; Rachelle H Crosbie; Stanley F Nelson; M Carrie Miceli
Journal:  Neuromuscul Disord       Date:  2019-09-24       Impact factor: 4.296

9.  Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy.

Authors:  Akinori Nakamura; Noboru Fueki; Naoko Shiba; Hirohiko Motoki; Daigo Miyazaki; Hitomi Nishizawa; Yusuke Echigoya; Toshifumi Yokota; Yoshitsugu Aoki; Shin'ichi Takeda
Journal:  J Hum Genet       Date:  2016-03-24       Impact factor: 3.172

10.  Survival in Duchenne muscular dystrophy.

Authors:  Susanne Rall; Tiemo Grimm
Journal:  Acta Myol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.